Acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome is often associated with IgG anti-GM1 and -GD1a antibodies. The pathophysiological basis of antibody-mediated selective motor nerve dysfunction remains unclear. We investigated the effects of IgG anti-GM1 and -GD1a monoclonal antibodies (mAbs) on neuromuscular transmission and calcium influx in hemidiaphragm preparations and in cultured neurons, respectively, to elucidate mechanisms of Ab-mediated muscle weakness. Anti-GM1 and -GD1a mAbs depressed evoked quantal release to a significant yet different extent, without affecting postsynaptic currents. At equivalent concentrations, anti-GD1b, -GT1b, or sham mAbs did not affect neuromuscular transmission. At fourfold higher concentration, an anti-GD1b mAb (specificity described in immune sensory neuropathies) induced completely reversible blockade. In neuronal cultures, anti-GM1 and -GD1a mAbs significantly reduced depolarizationinduced calcium influx. In conclusion, different anti-gangliosde mAbs induce distinct effects on presynaptic transmitter release by reducing calcium influx, suggesting that this is one mechanism of antibodymediated muscle weakness in AMAN.
Introduction
Anti-ganglioside antibodies (Abs) are implicated as primary immune effectors in acute motor axonal neuropathy (AMAN) and
Fisher syndrome (FS) variants of Guillain-Barré syndrome (GBS).
Recent studies show that IgG anti-GQ1b Abs in FS and IgG Abs to GD1a, GM1, and structurally related gangliosides are strongly associated with AMAN (Hughes et al., 1999; Latov, 1990; Willison and Yuki, 2002; Yuki, 2001) . Passive and active immunization models indicate that anti-GD1a and -GM1 antibodies produce axonal neuropathy (Sheikh et al., 2004; Yuki et al., 2001) . In contrast to AMAN, acute and chronic sensory ataxic neuropathies are associated with Abs to GD1b, with or without cross-reactivity to other gangliosides containing disialosyl moieties (Miyazaki et al., 2001; Willison et al., 1994) . Understanding the mechanism by which anti-ganglioside Abs with varied specificities produce distinct clinical features associated with different forms of GBS is an important pathobiologic issue relevant to several autoimmune neurological disorders.
Although in AMAN muscle weakness is the predominant clinical finding (McKhann et al., 1991; McKhann et al., 1993) , its pathophysiology remains incompletely defined. The following observations suggest that blockade of axonal conduction, in addition to motor axonal degeneration, contributes significantly to clinical weakness in AMAN. First, many patients with AMAN recover quite quickly, with or without intravenous immunoglobulin (IVIg) treatment, and their time course of recovery is incompatible with degeneration and regeneration of nerve fibers (Ho et al., 1997; Kuwabara et al., 1998) . Second, pathologic studies on AMAN patients and its rabbit model indicate that some subjects, despite severe flaccid paralysis and abnormal nerve conductions, do not show nerve fiber degeneration, raising the possibility that axonal degeneration is a late but not essential event in the pathogenesis of acute muscle weakness in AMAN (Griffin et al., 1996; Susuki et al., 2003) . Third, serial clinical electrophysiological observations in GBS cases with IgG anti-GM1 Abs (Kuwabara et al., 1998) show rapid recovery of CMAP amplitudes and motor conduction slowing without features of remyelination suggesting a reversible conduc-
